{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T14:50:51Z","timestamp":1785941451816,"version":"3.56.0"},"reference-count":80,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,12]]},"DOI":"10.1097\/01.grf.0000211955.61121.3b","type":"journal-article","created":{"date-parts":[[2006,10,11]],"date-time":"2006-10-11T04:28:14Z","timestamp":1160540894000},"page":"861-874","source":"Crossref","is-referenced-by-count":14,"title":["Antiphospholipid Syndrome and Thrombosis"],"prefix":"10.1097","volume":"49","author":[{"given":"D.","family":"WARE BRANCH","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ALEXANDRA GROSVENOR","family":"Eller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-16-20210126","doi-asserted-by":"crossref","first-page":"484","DOI":"10.3181\/00379727-48-13365P","article-title":"A new serologically active phospholipid from beef heart","volume":"48","author":"Pangborn","year":"1941","journal-title":"Proc Soc Exp Biol Med"},{"key":"R2-16-20210126","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1001\/jama.1952.03680050033010","article-title":"Biologically false positive serologic tests for syphilis","volume":"150","author":"Moore","year":"1952","journal-title":"JAMA"},{"key":"R3-16-20210126","first-page":"621","article-title":"A hemorrhagic disorder caused by circulating anticoagulant in patients with disseminated lupus erythematosus","volume":"31","author":"Conley","year":"1952","journal-title":"J Clin Invest"},{"key":"R4-16-20210126","first-page":"75","article-title":"Acquired inhibitors of blood coagulation","volume":"1","author":"Feinstein","year":"1972","journal-title":"Prog Hemostas Thromb"},{"key":"R5-16-20210126","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/S0140-6736(83)91267-9","article-title":"Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus","volume":"ii","author":"Harris","year":"1983","journal-title":"Lancet"},{"key":"R6-16-20210126","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1016\/0140-6736(90)91374-J","article-title":"Anticardiolipin antibodies directed not to cardiolipin but to a plasma protein cofactor","volume":"335","author":"Galli","year":"1990","journal-title":"Lancet"},{"key":"R7-16-20210126","doi-asserted-by":"crossref","first-page":"4120","DOI":"10.1073\/pnas.87.11.4120","article-title":"Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: b2-glycoprotein I (apolipoprotein H)","volume":"87","author":"McNeil","year":"1990","journal-title":"Proc Natl Acad Sci USA"},{"key":"R8-16-20210126","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0140-6736(90)91697-9","article-title":"Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease","volume":"336","author":"Matsuura","year":"1990","journal-title":"Lancet"},{"key":"R9-16-20210126","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","article-title":"International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)","volume":"4","author":"Miyakis","year":"2006","journal-title":"J Thromb Haemost"},{"key":"R10-16-20210126","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1160\/TH05-02-0081","article-title":"Variability of anti-beta2 glycoprotein I antibodies measurement by commercial assays","volume":"94","author":"Reber","year":"2005","journal-title":"Thromb Haemost"},{"key":"R11-16-20210126","first-page":"237","article-title":"Prothrombin as co-factor of the circulating anticoagulant in systemic lupus erythematosus?","volume":"3","author":"Loeliger","year":"1959","journal-title":"Thromb Diath Haemorrh"},{"key":"R12-16-20210126","first-page":"89","article-title":"Purification and kinetic studies on a circulating anticoagulant in a suspected case of lupus erythematosus","volume":"14","author":"Yin","year":"1965","journal-title":"Thromb Diath Haemorrh"},{"key":"R13-16-20210126","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1055\/s-0038-1656368","article-title":"Anticoagulant activity of b2-glycoprotien I is potentiated by a distinct subgroup of anticardiolipin antibodies","volume":"68","author":"Galli","year":"1992","journal-title":"Thromb Haemost"},{"key":"R14-16-20210126","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1055\/s-0038-1648480","article-title":"Lupus anticoagulant activity is frequently dependent on the presence of b2-glycoprotein I","volume":"67","author":"Oosting","year":"1992","journal-title":"Thromb Haemost"},{"key":"R15-16-20210126","first-page":"416","article-title":"Thrombosis in systemic lupus erythematosus despite circulating anticoagulants","volume":"62","author":"Bowie","year":"1963","journal-title":"J Lab Clin Med"},{"key":"R16-16-20210126","first-page":"65","article-title":"Acquired inhibitors in nonhemophilic patients","volume":"3","author":"Lechner","year":"1974","journal-title":"Haemostasis"},{"key":"R17-16-20210126","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.0954-6820.1975.tb04897.x","article-title":"Intrauterine death and circulating anticoagulant (\u201cantithromboplastin\u201d)","volume":"197","author":"Nilsson","year":"1975","journal-title":"Acta Med Scand"},{"key":"R18-16-20210126","first-page":"859","article-title":"Avortements \u00e0 r\u00e9p\u00e9tition, thrombose et anticoagulant circulant anti-thromboplastine","volume":"9","author":"Soulier","year":"1980","journal-title":"Nouv Presse Med"},{"key":"R19-16-20210126","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/S0140-6736(80)90361-X","article-title":"Possible relationship between lupus inhibitor and recurrent abortion in young women","volume":"2","author":"Firkin","year":"1980","journal-title":"Lancet"},{"key":"R20-16-20210126","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/S0140-6736(83)92141-4","article-title":"Fetal survival after prednisone suppression of maternal lupus anticoagulant","volume":"i","author":"Lubbe","year":"1983","journal-title":"Lancet"},{"key":"R21-16-20210126","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1056\/NEJM198507183130304","article-title":"Antibody to cardiolipin as a predictor of fetal distress or death in pregnant patients with systemic lupus erythematosus","volume":"313","author":"Lockshin","year":"1985","journal-title":"N Engl J Med"},{"key":"R22-16-20210126","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1056\/NEJM198511213132104","article-title":"Obstetric complications associated with the lupus anticoagulant","volume":"313","author":"Branch","year":"1985","journal-title":"N Engl J Med"},{"key":"R23-16-20210126","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1093\/rheumatology\/26.5.324","article-title":"Syndrome of the black swan","volume":"26","author":"Harris","year":"1987","journal-title":"Br J Rheumatol"},{"key":"R24-16-20210126","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1002\/art.10187","article-title":"Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients","volume":"46","author":"Cervera","year":"2002","journal-title":"Arthritis Rheum"},{"key":"R25-16-20210126","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1097\/00005792-198911000-00004","article-title":"The \u201cprimary\u201d antiphospholipid syndrome: major clinical and serological features","volume":"68","author":"Asherson","year":"1989","journal-title":"Medicine (Baltimore)"},{"key":"R26-16-20210126","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/0049-0172(92)90021-5","article-title":"Preliminary classification criteria for the antiphospholipid syndrome within systemic lupus erythematosus","volume":"21","author":"Alarc\u00f3n-Segovia","year":"1992","journal-title":"Semin Arthritis Rheum"},{"key":"R27-16-20210126","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/0002-9343(94)90108-2","article-title":"Comparison of the primary and secondary antiphospholipid syndrome: a European multicenter study of 114 patients","volume":"96","author":"Vianna","year":"1994","journal-title":"Am J Med"},{"key":"R28-16-20210126","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1056\/NEJMra002974","article-title":"The Antiphospholipid Syndrome","volume":"346","author":"Levine","year":"2002","journal-title":"N Engl J Med"},{"key":"R29-16-20210126","first-page":"1333","article-title":"Antiphospholipid syndrome: obstetric diagnosis, management, and controversies","volume":"101","author":"Branch","year":"2003","journal-title":"Obstet Gynecol"},{"key":"R30-16-20210126","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/S0015-0282(16)58565-3","article-title":"Antiphospholipid antibody panels and recurrent pregnancy loss: prevalence of anticardiolipin antibodies compared with other antiphospholipid antibodies","volume":"66","author":"Yetman","year":"1996","journal-title":"Fertil Steril"},{"key":"R31-16-20210126","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S0029-7844(97)00065-3","article-title":"Antiphospholipid antibodies other than lupus anticoagulant and anticardiolipin antibodies in women with recurrent pregnancy loss, fertile controls, and antiphospholipid syndrome","volume":"89","author":"Branch","year":"1997","journal-title":"Obstet Gynecol"},{"key":"R32-16-20210126","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1016\/0002-9378(92)91596-3","article-title":"Repeated fetal losses associated with antiphospholipid antibodies: a collaborative randomized trial comparing prednisone with low-dose heparin treatment","volume":"166","author":"Cowchock","year":"1992","journal-title":"Am J Obstet Gynecol"},{"key":"R33-16-20210126","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1016\/0002-9378(93)90410-K","article-title":"Comparative trial of prednisone plus aspirin versus aspirin alone in the treatment of anticardiolipin antibody-positive obstetric patients","volume":"169","author":"Silver","year":"1993","journal-title":"Am J Obstet Gynecol"},{"key":"R34-16-20210126","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1016\/S0002-9378(96)70610-5","article-title":"Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone","volume":"174","author":"Kutteh","year":"1996","journal-title":"Am J Obstet Gynecol"},{"key":"R35-16-20210126","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1136\/bmj.314.7076.253","article-title":"Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies","volume":"314","author":"Rai","year":"1997","journal-title":"Br Med J"},{"key":"R36-16-20210126","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1067\/mob.2000.106754","article-title":"Does aspirin have a role in improving pregnancy outcome for women with the antiphospholipid syndrome? A randomized controlled trial","volume":"183","author":"Pattison","year":"2000","journal-title":"Am J Obstet Gynecol"},{"key":"R37-16-20210126","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1097\/00006250-200212000-00032","article-title":"Antiphospholipid syndrome in pregnancy: a randomized, controlled trial of treatment","volume":"100","author":"Farquharson","year":"2002","journal-title":"Obstet Gynecol"},{"key":"R38-16-20210126","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/0140-6736(90)91373-I","article-title":"Association of antibodies against phospholipids with heart valve disease in systemic lupus erythematosus","volume":"335","author":"Khamashta","year":"1990","journal-title":"Lancet"},{"key":"R39-16-20210126","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/0002-9343(89)90335-5","article-title":"Cerebrovascular disease and antiphospholipid antibodies in systemic lupus erythematosus, lupus-like disease, and the primary antiphospholipid syndrome","volume":"86","author":"Asherson","year":"1989","journal-title":"Am J Med"},{"key":"R40-16-20210126","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1212\/01.WNL.0000149640.78684.EA","article-title":"Predictors of cognitive dysfunction in patients with systemic lupus erythematosus","volume":"64","author":"McLaurin","year":"2005","journal-title":"Neurology"},{"key":"R41-16-20210126","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/S0889-857X(21)00209-X","article-title":"Neurologic complications of antiphospholipid antibodies","volume":"19","author":"Brey","year":"1993","journal-title":"Rheum Dis Clin North Am"},{"key":"R42-16-20210126","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S0002-9378(11)90700-5","article-title":"IgG fractions from patients with antiphospholipid antibodies cause fetal death in BALB\/c mice: a model for autoimmune fetal loss","volume":"163","author":"Branch","year":"1990","journal-title":"Am J Obstet Gynecol"},{"key":"R43-16-20210126","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1084\/jem.200116116","article-title":"Complement C3 activation is required for antiphospholipid antibody-induced fetal loss","volume":"195","author":"Holers","year":"2002","journal-title":"J Exp Med"},{"key":"R44-16-20210126","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1055\/s-0038-1642501","article-title":"Effect of human IgG antiphospholipid antibodies on an in vivo thrombosis model in mice","volume":"71","author":"Pierangeli","year":"1994","journal-title":"Thromb Haemost"},{"key":"R45-16-20210126","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1046\/j.1365-2141.2003.04304.x","article-title":"The concomitant presence of lupus anticoagulant, anticardiolipin and anti-beta2-glycoprotein I antibodies could be associated with acquired activated protein C resistance in non-systemic lupus erythematosus patients","volume":"121","author":"Gennari","year":"2003","journal-title":"Br J Haematol"},{"key":"R46-16-20210126","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1182\/blood-2005-01-0404","article-title":"Inhibition of APC anticoagulant activity on oxidized phospholipid by anti-beta2-glycoprotein I monoclonal antibodies","volume":"106","author":"Safa","year":"2005","journal-title":"Blood"},{"key":"R47-16-20210126","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1373\/clinchem.2004.043414","article-title":"Acquired activated protein C resistance associated with IgG antibodies against-\u03b22-glycoprotein I and prothrombin as a strong risk factor for venous thromboembolism","volume":"51","author":"Nojima","year":"2005","journal-title":"Clin Chem"},{"key":"R48-16-20210126","doi-asserted-by":"crossref","first-page":"954","DOI":"10.4049\/jimmunol.154.2.954","article-title":"\u201cAnticardiolipin\u201d autoantibodies recognize b2-glycoprotein I in the absence of phospholipid. Importance of antigen density and bivalent binding","volume":"154","author":"Roubey","year":"1995","journal-title":"J Immunol"},{"key":"R49-16-20210126","doi-asserted-by":"crossref","first-page":"13833","DOI":"10.1021\/bi960657q","article-title":"Role of divalency in the high affinity binding of cardiolipin antibody- \u03b22-glycoprotein I complexes to lipid membranes","volume":"35","author":"Willems","year":"1996","journal-title":"Biochemistry"},{"key":"R50-16-20210126","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1182\/blood-2004-08-3145","article-title":"Binding of \u03b22\u2013glycoprotein I to anionic phospholipids facilitates processing and presentation of a cryptic epitope that activates pathogenic autoreactive T cells","volume":"105","author":"Kuwana","year":"2005","journal-title":"Blood"},{"key":"R51-16-20210126","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1182\/blood-2002-05-1310","article-title":"Thrombogenicity of beta 2-glycoprotein i-dependent antiphospholipid antibodies in a photochemically induced thrombosis model in the hamster","volume":"101","author":"Jankowski","year":"2003","journal-title":"Blood"},{"key":"R52-16-20210126","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1111\/j.1538-7836.2005.01359.x","article-title":"Pathophysiology of the antiphospholipid syndrome","volume":"3","author":"de Groot","year":"2005","journal-title":"J Thromb Haemost"},{"key":"R53-16-20210126","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1182\/blood-2002-08-2349","article-title":"Role of the MyD88 transduction signaling pathway in endothelial activation by antiphospholipid antibodies","volume":"101","author":"Raschi","year":"2003","journal-title":"Blood"},{"key":"R54-16-20210126","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1182\/blood-2004-05-1708","article-title":"Annexin A2 mediates endothelial cell activation by antiphospholipid\/anti-beta2 glycoprotein I antibodies","volume":"105","author":"Zhang","year":"2005","journal-title":"Blood"},{"key":"R55-16-20210126","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1055\/s-0037-1607384","article-title":"Functional analyses of patient-derived IgG monoclonal anticardiolipin antibodies using in vivo thrombosis and in vivo microcirculation models","volume":"84","author":"Pierangeli","year":"2000","journal-title":"Thromb Haemost"},{"key":"R56-16-20210126","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1172\/JCI200318817","article-title":"Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome","volume":"112","author":"Girardi","year":"2003","journal-title":"J Clin Invest"},{"key":"R57-16-20210126","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1002\/art.21157","article-title":"Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia","volume":"52","author":"Pierangeli","year":"2005","journal-title":"Arthritis Rheum"},{"key":"R58-16-20210126","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1038\/nm1121","article-title":"Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation","volume":"10","author":"Girardi","year":"2004","journal-title":"Nat Med"},{"key":"R59-16-20210126","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jri.2005.01.006","article-title":"Heparin treatment in pregnancy loss: potential therapeutic benefits beyond anticoagulation","volume":"66","author":"Girardi","year":"2005","journal-title":"J Reprod Immunol"},{"key":"R60-16-20210126","doi-asserted-by":"crossref","first-page":"485","DOI":"10.4049\/jimmunol.174.1.485","article-title":"TNF-alpha is a critical effector and a target for therapy in antiphospholipid antibody-induced pregnancy loss","volume":"174","author":"Berman","year":"2005","journal-title":"J Immunol"},{"key":"R61-16-20210126","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1093\/humrep\/deh844","article-title":"Recurrent miscarriage and long-term thrombosis risk: a case-control study","volume":"20","author":"Quenby","year":"2005","journal-title":"Hum Reprod"},{"key":"R62-16-20210126","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1182\/blood-2002-11-3334","article-title":"Anti-beta 2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome","volume":"102","author":"Galli","year":"2003","journal-title":"Blood"},{"key":"R63-16-20210126","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/j.1445-5994.1990.tb01025.x","article-title":"Prevalence of lupus anticoagulant and anticardiolipin antibodies in a healthy population","volume":"20","author":"Shi","year":"1990","journal-title":"Aust N Z J Med"},{"key":"R64-16-20210126","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1055\/s-0038-1648840","article-title":"Prevalence, follow-up and clinical significance of the anticardiolipin antibodies in normal subjects","volume":"72","author":"Vila","year":"1994","journal-title":"Thromb Haemost"},{"key":"R65-16-20210126","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1182\/blood-2002-02-0441","article-title":"Lupus anticoagulants are stronger risk factors of thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature","volume":"101","author":"Galli","year":"2003","journal-title":"Blood"},{"key":"R66-16-20210126","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1111\/j.1538-7836.2005.01485.x","article-title":"Lupus anticoagulants and the risk of a first episode of deep venous thrombosis","volume":"3","author":"de Groot","year":"2005","journal-title":"J Thromb Haemost"},{"key":"R67-16-20210126","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1046\/j.1365-2141.2002.03949.x","article-title":"Anticardiolipin antibodies as a risk factor for venous thromboembolism in a population-based prospective study","volume":"119","author":"Runchey","year":"2002","journal-title":"Br J Haematol"},{"key":"R68-16-20210126","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1538-7836.2005.01691.x","article-title":"A prospective study of anticardiolipin antibodies as a risk factor for venous thrombosis in a general population (the HUNT study)","volume":"4","author":"Naess","year":"2006","journal-title":"J Thromb Haemost"},{"key":"R69-16-20210126","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1161\/01.STR.0000117575.48205.2D","article-title":"Anticardiolipin antibodies and risk of ischemic stroke and transient ischemic attack: the Framingham cohort and off-spring study","volume":"35","author":"Janardhan","year":"2004","journal-title":"Stroke"},{"key":"R70-16-20210126","doi-asserted-by":"crossref","first-page":"191","DOI":"10.3109\/03009749609069986","article-title":"Thrombosis and systemic lupus erythematosus: the Hopkins Lupus Cohort perspective","volume":"25","author":"Petri","year":"1996","journal-title":"Scand J Rheumatol"},{"key":"R71-16-20210126","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1093\/rheumatology\/41.8.924","article-title":"A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome","volume":"41","author":"Erkan","year":"2002","journal-title":"Rheumatology"},{"key":"R72-16-20210126","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1002\/1529-0131(200106)44:6<1466::AID-ART242>3.0.CO;2-C","article-title":"High thrombosis rate after fetal loss in antiphospholipid syndrome: effective prophylaxis with aspirin","volume":"44","author":"Erkan","year":"2001","journal-title":"Arthritis Rheum"},{"key":"R73-16-20210126","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.rdc.2005.09.004","article-title":"New treatments for antiphospholipid syndrome","volume":"32","author":"Erkan","year":"2006","journal-title":"Rheum Dis Clin North Am"},{"issue":"3","key":"R74-16-20210126","doi-asserted-by":"crossref","first-page":"401S","DOI":"10.1378\/chest.126.3_suppl.401S","article-title":"Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy","volume":"126","author":"Buller","year":"2004","journal-title":"Chest"},{"key":"R75-16-20210126","doi-asserted-by":"crossref","first-page":"303","DOI":"10.7326\/0003-4819-117-4-303","article-title":"Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients","volume":"117","author":"Rosove","year":"1992","journal-title":"Ann Intern Med"},{"key":"R76-16-20210126","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJM199504133321504","article-title":"The management of thrombosis in the antiphospholipid-antibody syndrome","volume":"332","author":"Khamashta","year":"1995","journal-title":"N Engl J Med"},{"key":"R77-16-20210126","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/S0002-9343(98)00060-6","article-title":". Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy","volume":"104","author":"Schulman","year":"1998","journal-title":"Am J Med"},{"key":"R78-16-20210126","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1056\/NEJMoa035241","article-title":"A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome","volume":"349","author":"Crowther","year":"2003","journal-title":"N Engl J Med"},{"key":"R79-16-20210126","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1111\/j.1538-7836.2005.01340.x","article-title":"A randomized clinical trial of high-intensity warfarin vs conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS)","volume":"3","author":"Finazzi","year":"2005","journal-title":"J Thromb Haemost"},{"key":"R80-16-20210126","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1001\/jama.295.9.1050","article-title":"Management of antiphospholipid antibody syndrome: a systematic review","volume":"295","author":"Lim","year":"2006","journal-title":"JAMA"}],"container-title":["Clinical Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00003081-200612000-00016","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T14:13:09Z","timestamp":1785939189000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00003081-200612000-00016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,12]]},"references-count":80,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2006]]}},"URL":"https:\/\/doi.org\/10.1097\/01.grf.0000211955.61121.3b","relation":{},"ISSN":["0009-9201"],"issn-type":[{"value":"0009-9201","type":"print"}],"subject":[],"published":{"date-parts":[[2006,12]]}}}